Abich Financial Wealth Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Abich Financial Wealth Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$68K	Buy	+1,632	New	+$52.2K	0.02%	271

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Abich Financial Wealth Management's CRNX Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q3 2025: 1,632 shares worth $68K. The stake represents 0.02% of the portfolio and ranks #271 among its holdings.

225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

Abich Financial Wealth Management held 1,632 shares of Crinetics Pharmaceuticals worth $68K as of Q3 2025.
Crinetics Pharmaceuticals was a new Abich Financial Wealth Management position in Q3 2025.
Crinetics Pharmaceuticals made up 0.02% of Abich Financial Wealth Management's portfolio in Q3 2025, its #271 holding.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.